Navigation Links
Compendia Bioscience and H3 Biomedicine Announce Strategic Collaboration to Apply Cancer Genomics to Discover and Develop Next Generation Cancer Therapeutics
Date:2/14/2012

ANN ARBOR, Mich. and CAMBRIDGE, Mass., Feb. 14, 2012 /PRNewswire-USNewswire/ -- Compendia Bioscience today announced that it has signed a three-year licensing agreement with H3 Biomedicine, Inc. to Compendia's full suite of Oncomine tools including Oncomine Concepts Edition and Oncomine Power Tools Edition.

In addition, Compendia and H3 will work together to mine data from The Cancer Genome Atlas (TCGA) to discover novel therapeutic targets and biomarkers to support drug development.

 "We are really excited to welcome H3 Biomedicine as a new partner and customer," said Daniel Rhodes, Ph.D., Compendia's co-founder and CEO. "H3 has developed a unique and compelling business strategy that is perfectly aligned with Compendia's vision for cancer drug discovery and development. We could not be more pleased to be working with them to make their vision into a reality."

"Compendia is the clear and recognized industry leader in applying cancer genomics to the discovery and development of cancer therapeutics," said Dr. Markus Warmuth, the CEO of H3 Biomedicine. "As we aim to develop H3 into a potent cancer drug discovery enterprise, it is clear that we need to partner with companies such as Compendia that think about cancer in the same way we do, that believe the development of cancer therapeutics begins with a clear understanding of the molecular characteristics and diversity of cancer patients."

About Compendia Bioscience, Inc.

Compendia Bioscience is dedicated to curing cancers through the application of genomic data by providing researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes. Visit www.compendiabio.com for more information.

About Oncomine™

Oncomine combines a rapidly growing compendium of 62,000+ expertly curated cancer genomic profiles with a sophisticated analysis engine and powerful web applications for data mining and visualization. Oncomine facilitates target discovery and validation and supports the prioritization of tumor populations for drug development. Visit www.oncomine.com for more information.

About H3 Biomedicine Inc.

H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit www.H3biomedicine.com for more information.

About Eisai Inc.

Eisai Inc. was established in 1995 and began marketing its first product in the United States in 1997. Since that time, Eisai Inc. has rapidly grown to become a fully integrated pharmaceutical business. Eisai's key areas of commercial focus are neurology and oncology. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as manufacturing facilities in Maryland and North Carolina. The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit www.eisai.com/US.


'/>"/>
SOURCE Compendia Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AAIPharma Services Announces 24/7 Online Compendial Raw Materials Testing
2. AAIPharma Services Announces Compendial Testing Facility Expansion
3. On Second Anniversary, Compendia Bioscience Announces Significant Revenue Growth, Completion of Product Milestone and Expansion of Pharma Customer Commitments
4. PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
5. INVO Bioscience Announces Approval of INVOcell by Brazils ANVISA
6. Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock
7. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
8. Roka Bioscience Awarded AOAC-RI Certification for Roka Listeria Detection Assay
9. Ambit Biosciences to Present at 30th Annual J.P. Morgan Healthcare Conference
10. Neurocrine Biosciences to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/13/2017)... 2017 Eli Lilly and Company (NYSE: ... INCY ) announced today that the U.S. Food and ... the new drug application (NDA) for investigational baricitinib, a ... severe rheumatoid arthritis (RA). The NDA for baricitinib was ... The FDA extended the action date to allow time ...
(Date:1/13/2017)... -- Wichita Laser Clinic at Healthy Life ... Wichita, Kansas featuring the Astanza Revolution ... rejuvenation, getting rid of unwanted tattoos, killing toenail fungus, ... "Since being in the aesthetics industry, I have ... for laser tattoo removal and other popular cosmetic ...
(Date:1/13/2017)... , Jan. 12, 2017   JDRF ... diabetes (T1D) research, is pleased to announce that ... the Centers for Medicare & Medicaid Services (CMS) ... by the FDA for use in making diabetes ... step toward making them eligible for coverage under ...
Breaking Medicine Technology:
(Date:1/14/2017)... ... , ... AgileMinder develops innovative products and services that bring "Care, Joy and ... Apple as a fun, free emoji sticker pack for iMessage. Use the stickers in ... coded values on The Emoji Scale. , On Apple: "The Emoji Scale by ...
(Date:1/13/2017)... ... January 13, 2017 , ... The 18th European Congress: ... hotel on March 3-4, 2017. This Congress is expertly designed to meet the ... of patients with lung cancer. , Chaired by Dr. Giorgio V. Scagliotti, Professor of ...
(Date:1/13/2017)... ... 2017 , ... With the increasing public preference for chemical-free ... organic alternatives for customers who have grown more conscious about maintaining their health ... activated charcoal products, Moody Zook Chief Executive Officer Nate Ginsburg explained their company’s ...
(Date:1/13/2017)... ... January 13, 2017 , ... People who have sensitive teeth ... pain whenever they brush their teeth. Sadly, most dental hygiene products in the market ... and teeth. For these people, continuing their daily oral care routine to keep their ...
(Date:1/13/2017)... ... January 13, 2017 , ... ... the Finnleo factory in Cokato, MN, with the official send-off from Orchestra Hall ... Maestro Osmo Vanska , Minnesota Orchestra’s Music Director, leading the official launch of ...
Breaking Medicine News(10 mins):